BioSpace News Archive

Amylyx Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.

Xeris Biopharma Holdings, Inc. announced financial results for the first quarter ended March 31, 2024 and recent events.

Orthofix Medical Inc., a leading global spine and orthopedics company, announced that it has received U.S. Food and Drug Administration 510 clearance to market its Rodeo™ Telescopic Nail. This press release features multimedia.

Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

LENSAR, Inc. today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives.

ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET.

PureTech Health plc today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

Apyx Medical Corporation today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024.

Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, reported operational highlights and financial results for the first quarter ended March 31, 2024.

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system diseases, reported financial results for its fiscal quarter ended March 31, 2024.